Committee opinion no. 641: Human papillomavirus vaccination

Obstetrics and Gynecology

Volumn 126, Issue 3, 2015, Pages e38-e43

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADVISORY COMMITTEE; CONDYLOMA ACUMINATUM; DISEASE CONTROL; DRUG SAFETY; HEALTH CARE SYSTEM; HUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RECTUM CANCER; REVACCINATION; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION;

EID: 84939644404     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000471170.79174.84     Document Type: Review

References (29)

1. Centers for Disease Control and Prevention. HPV and cancer. Available at: http://www.cdc.gov/hpv/cancer.html. Retrieved June 8, 2015
2. Merck & Company, Inc. Gardasil® 9 (human papilloma-virus 9-valent vaccine, recombinant): highlights of pre-scribing information. Whitehouse Station (NJ): Merck; 2014. Available at: http://www.fda.gov/downloads/Biologics BloodVaccines/Vaccines/ApprovedProducts/UCM426457. pdf. Retrieved June 9, 2015
3. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7: 38. [PubMed] [Full Text
4. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. HPV Typing of Cancers Workgroup. J Natl Cancer Inst 2015; doi: 10.1093/jnci/djv086. [PubMed] [Full Text
5. Hariri S, Unger ER, Schafer S, Niccolai LM, Park IU, Bloch KC, et al. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. HPV-IMPACT Working Group. Cancer Epidemiol Biomarkers Prev 2015; 24: 393-9. [PubMed
6. FDA licensure of bivalent human papillomavirus vac-cine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC) [published erratum appears in MMWR Morb Mortal Wkly Rep 2010; 59: 1184]. MMWR Morb Mortal Wkly Rep 2010; 59: 626-9. [PubMed] [Full Text
7. Merck & Company, Inc. FDA approves Merck's HPV vac-cine, Gardasil® 9, to prevent cancers and other diseases caused by nine HPV types -including types that cause about 90% of cervical cancer cases. Kenilworth (NJ): Merck; 2014. Available at: https://www.merckvaccines.com/is-bin/intershop.static/WFS/Merck-MerckVaccines-Site/Merck-MerckVaccines/en-US/Professional-Resources/Documents/announcements/VACC-1133406-0000.pdf. Retrieved June 9, 2015
8. Wierzbicka M, Jozefiak A, Jackowska J, Szydlowski J, Gozdzicka-Jozefiak A. HPV vaccination in head and neck HPV-related pathologies. Otolaryngol Pol 2014; 68: 157-73. [PubMed] [Full Text
9. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208: 385-93. [PubMed] [Full Text
10. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2014; 63: 620-4. [PubMed] [Full Text
11. Rowhani-Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS, et al. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 2012; 53: 239-43. [PubMed] [Full Text
12. Bednarczyk RA, Davis R, Ault K, Orenstein W, Omer SB.Sexual activity-related outcomes after human papillo-mavirus vaccination of 11-to 12-year-olds. Pediatrics 2012; 130: 798-805. [PubMed] [Full Text
13. Schiller JT, Castellsague X, Garland SM. A review of clini-cal trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(suppl 5): F123-38. [PubMed
14. Eaton DK, Kann L, Kinchen S, Shanklin S, Ross J, Hawkins J, et al. Youth risk behavior surveillance-United States, 2009. Centers for Disease Control and Prevention (CDC). MMWR Surveill Summ 2010; 59(SS-5): 1-142. [PubMed] [Full Text
15. Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vac-cine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 2013; 105: 469-74. [PubMed] [Full Text
16. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papilloma-virus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39. [PubMed] [Full Text
17. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. HPV PATRICIA Study Group [published erratum appears in Lancet 2010; 376: 1054]. Lancet 2009; 374: 301-14. [PubMed] [Full Text
18. Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommenda-tions of the advisory committee on immunization prac-tices. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2015; 64: 300-4. [PubMed] [Full Text
19. Centers for Disease Control and Prevention. Vaccine safety: human papillomavirus (HPV) vaccine. Available at: http://www.cdc.gov/vaccinesafety/vaccines/HPV/index.html. Retrieved June 8, 2015
20. Merck & Company, Inc. Gardasil® 9 (human papillomavi-rus 9-valent vaccine, recombinant): highlights of prescrib-ing information. Whitehouse Station (NJ): Merck; 2015.Available at: http://www.merck.com/product/usa/pi-circulars/g/gardasil-9/gardasil-9-pi.pdf. Retrieved June 9,2015
21. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized con-trolled trials. Quadrivalent Human Papillomavirus Vaccine Phase III Investigators. Obstet Gynecol 2009; 114: 1179-88. [PubMed] [Obstetrics & Gynecology
22. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8: 390-7. [PubMed] [Full Text
23. GlaxoSmithKline Biologicals. Cervarix: highlights of pre-scribing information. Research Triangle Park (NC): GSK; 2015. Available at: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing-Information/Cervarix/pdf/CERVARIX-PI-PIL.PDF. Retrieved June 9, 2015
24. Merck & Company, Inc. Gardasil® [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombi-nant]: highlights of prescribing information. Whitehouse Station (NJ): Merck; 2015. Available at: http://www.merck.com/product/usa/pi-circulars/g/gardasil-9/gardasil-9-pi.pdf. Retrieved June 9, 2015
25. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-2): 1-24. [PubMed] [Full Text
26. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. IMPAACT P1047 Protocol Team. J Acquir Immune Defic Syndr 2010; 55: 197-204. [PubMed] [Full Text
27. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vac-cine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309: 1793-802. [PubMed] [Full Text
28. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2000; 9: 47-50. [PubMed] [Full Text
29. Human papillomavirus vaccination coverage among ado-lescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 -United States. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2013; 62: 591-5. [PubMed] [Full Text